Author

A. Mandl

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

B. Hanratty· 1 shared D. Rosen· 1 shared H. Rienhoff· 1 shared I. Coleman· 1 shared J. Beumer· 1 shared J. Isaacs· 1 shared L. Antony· 1 shared L. Sena· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

B. Hanratty

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Differential response to LSD1 inhibition in prostate cancer reveals a YAP1 vulnerability in the neuroendocrine subtype

S. Jasim, R. Kumar, S. Kim, T. Krueger, I. Coleman, S. Dalrymple, L. Antony, D. Rosen, B. Hanratty, R. Patel, P. Nelson, Z. Aghaei, J. Beumer, M. Haffner, T. Lotan, , W. Brennen

This paper shows that LSD1 inhibition is effective against neuroendocrine prostate cancer (NEPC) and that combining it with YAP/TEAD inhibition enhances treatment efficacy.

bioRxiv · Jan 17, 2024 · PreprintCancer Biology